The development of these mutations following anti-EGFR targeted treatment, can be a consequence of alterations rising from pre-existent KRAS altered clones, or due to new mutations derived from stress conditions induced by targeted therapy to the tumor and tumor microenvironment. This evidence concerns the gene EGFR and neoplasm.